Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Editas MedicineEDIT -3.54%57 3-Year Share Buyback Ratio is -12.40 as of Jun. 2026. GuruFocus rates EDIT with a GF Score™ of 57/100 and a GF Value™ of $2.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,190 Biotechnology companies, Editas Medicine ranks worse than 51.43% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Editas Medicine's current 3-Year Share Buyback Ratio was -12.40%.
The historical rank and industry rank for Editas Medicine's 3-Year Share Buyback Ratio or its related term are showing as below:
EDIT'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9 Med: -10.15 Max: -0.1
Current: -12.4
During the past 13 years, Editas Medicine's highest 3-Year Share Buyback Ratio was -0.10%. The lowest was -14.90%. And the median was -10.15%.
EDIT's 3-Year Share Buyback Ratio is ranked worse than 51.43% of 1190
companies
in the Biotechnology industry
Industry Median: -11.8
vs EDIT: -12.40
Editas Medicine (NAS:EDIT) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Editas Medicine 3-Year Share Buyback Ratio Related Terms
EDIT vs BNTC, PBYI, EVMN: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Editas Medicine's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Editas Medicine's 3-Year Share Buyback Ratio falls into.
Editas Medicine 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -12.40 mean?
Editas Medicine (EDIT) has a 3-Year Share Buyback Ratio of -12.40 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #612 out of 1190 companies in the Biotechnology industry, placing it in the top 51.4%.
Is Editas Medicine's 3-Year Share Buyback Ratio too high?
Editas Medicine's current 3-Year Share Buyback Ratio is -12.40. Based on the distribution chart, Editas Medicine ranks #612 out of 1190 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Editas Medicine has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's 3-Year Share Buyback Ratio compare to BNTC and PBYI?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #612 out of 1190 companies for 3-Year Share Buyback Ratio. This places Editas Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Editas Medicine and its competitors. Editas Medicine's current 3-Year Share Buyback Ratio is -12.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.27, compared to a current price of $3.01 — trading 32.4% above its estimated fair value. The current 3-Year Share Buyback Ratio is -12.40. Editas Medicine's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Editas Medicine (EDIT), the current 3-Year Share Buyback Ratio is -12.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $3.01 is trading 32.4% above its estimated GF Value™ of $2.27.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
3-Year Share Buyback Ratio: -12.40
GF Value™: $2.27 vs. price of $3.01 (32.4% above fair value)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
57GF Score
Get the complete analysis for EDIT
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
